logo
logo

Bridge Medicines Announces Additional Funding of $10 Million from Inside Investors

Nov 12, 2020•over 4 years ago

Amount Raised

$10 Million

New York

Description

Bridge Medicines, a pioneering drug discovery company focused on advancing promising early technologies from concept to clinic, announced today the additional funding of $10 million to advance its current pipeline of products as well as expand with additional in-licensed technologies.

Company Information

Company

Bridge Medicines

Location

New York, New York, United States

About

Bridge Medicines is a pioneering drug-discovery company focused on advancing promising early technologies in major academic institutions from proof-of-concept to clinical development. Launched by Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, and Takeda Pharmaceutical Company Limited, in partnership with Deerfield Management Company and Bay City Capital, Bridge Medicines is a groundbreaking initiative that provides an unbroken, fully funded and professionally staffed path from discovery to drug candidate.  For more information about Bridge Medicines, please visit www.BridgeMedicines.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech